IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information and Indications
INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
Please see full Prescribing Information for INLYTA.